Opsonix
Cambridge
About Opsonix
Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $9.2M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Oct 2017)
- Website: opsonixbio.com
- Phone: 617-444-8644
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/opsonix-139373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.